HOME_PAGE_HEADER_CONTENT

A female patient and a female physician, representing different ethnicities in conversation A female patient and a female physician, representing different ethnicities in conversation

Passion for Innovation.
Compassion for Patients.®

Creating New Standards of Care

Creating New Standards of Care

We create essential medicine for longer, better lives.

Learn More About Our Purpose

RecentStoryCarousel

Our Stories

Everyone at Daiichi Sankyo has a unique craft - a skill or expertise that they hone with relentless dedication. Our inclusive and diverse community of collaborators apply their individual expertise with compassion to innovate for patients. View More Stories

Understanding Metastatic Breast Cancer: Exploring the Science

Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.

Learn more
Cherry Blossoms in Washington, D.C. Source of Pride for Daiichi Sankyo

Daiichi Sankyo honors its Japanese heritage and connection to the cherry blossom trees in Washington, D.C. as a perennial sponsor of the National Cherry Blossom Festival. Learn about the special link and watch a video capturing the joy felt by Daiichi Sankyo employees participating in the festival parade.

Learn more

Transforming Science into Medicines

Transforming Science into Medicines

By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.

Learn More About Our Science
2 women in lab coats looking at a sample

Dxd Section

Striving to Create Optimized Antibody Drug Conjugate (ADC) Technology

DXd ADC Technology: Our innovations deliver on the benefits of ADC technology.

Explore the DXd ADC Technology Website

Featured News

What's New

Read our press releases and learn more about our latest breakthroughs in medicine. View More News

Mon Jun 02 00:00:00 GMT-05:00 2025

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 Trial

Daiichi Sankyo and AstraZeneca’s ENHERTU plus pertuzumab showed a median progression-free survival greater than three years First trial in more than a decade to demonstrate an improvement in outcomes in the first-line setting for a broad population of patients with HER2 positive metastatic breast cancer

Learn more

Sun Jun 01 00:00:00 GMT-05:00 2025

DATROWAY® Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for advanced or metastatic NSCLC. TROPION-Lung02 results include first exploratory QCS analysis of DATROWAY in first-line setting. NeoCOAST-2 phase 2 results continue to show potential for DATROWAY plus durvalumab and single-agent platinum chemotherapy in neoadjuvant setting.

Learn more

New Home Pipeline

A Pipeline Pushing Us to Become a Global Leader in Oncology

Working with care and dedication, we’re developing new therapies that address the greatest needs in healthcare, making bold strides in cancer and other diseases.

Learn More About Our Medicines

New Home With Purpose

Work with a Purpose

Be part of something extraordinary. Our people are our most important asset, and we enable them to bring their best selves to work.

Join Our Team
Office employee sitting listening to conversation